Black Diamond completes Phase 2 enrollment for silevertinib; net loss narrows to $10.6M

Black Diamond Therapeutics, Inc.

2025-Q2 EPS reported $0.80 revenue$70,000,000

Cash $142.8M (vs $98.6M Dec 2024) funds operations into Q4 2027.
Net loss $10.6M in Q2 2025 vs $19.9M in Q2 2024; R&D expenses down to $9.3M.
Phase 2 trial of silevertinib in 1L non-classical EGFRm NSCLC fully enrolled (n=43); ORR & preliminary DOR data expected Q4 2025.
Exploring partnership opportunities for silevertinib in NSCLC and GBM; FDA meeting planned for 1H 2026 on registrational path.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.